fda compounding restrictions
Stop Using Compounded Meds, Rethink Prescription Weight Loss
The FDA’s new rule removes semaglutide, tirzepatide and liraglutide from the 503B bulk list, meaning patients will lose the low-cost compounded option and may see monthly prices rise as much as 30 percent. Did you know the FDA’s sudden ruling could lift the monthly bill for your weight-loss